Improving Blood Culture Diagnostic Reliability in Viet Nam: Collection Adequacy, Contamination Surveillance and Interpretation Safeguards
DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT
11/5/202621 min read


Improving Blood Culture Diagnostic Reliability in Viet Nam: Collection Adequacy, Contamination Surveillance and Interpretation Safeguards
When a blood culture becomes positive, the most important question is not simply which microorganism has been detected. It is whether the finding represents a genuine bloodstream infection, contamination introduced during specimen collection, or a result whose clinical significance remains uncertain.
The distinction matters. A contaminated blood culture may lead to unnecessary antimicrobial treatment, additional investigations, or prolonged hospitalization. Conversely, a negative result obtained from an inadequate specimen may provide false reassurance when bloodstream infection remains clinically possible.
Blood cultures are essential investigations for detecting bacteria and fungi in the bloodstream, particularly when clinicians suspect sepsis or other serious infections. Their diagnostic value, however, depends on more than the laboratory's ability to detect microbial growth. The amount of blood collected, the number and configuration of culture sets, prior antimicrobial exposure, collection technique, and interpretation of recovered organisms all influence how much confidence can be placed in the result.
For healthcare organizations, this creates a quality challenge that extends beyond the laboratory. A hospital may operate sophisticated automated blood culture equipment but still produce clinically misleading information if specimen collection, handling, or interpretation is not adequately controlled.
Recent international guidance has reinforced the importance of examining these processes together. The Clinical and Laboratory Standards Institute (CLSI) provides established technical recommendations, while the United States Centers for Disease Control and Prevention (CDC) has developed measures for monitoring blood culture contamination and single-set collection. The 2026 Surviving Sepsis Campaign guidelines and recent diagnostic stewardship research offer further insights into appropriate testing and interpretation.
For healthcare organizations in Viet Nam, improving blood culture reliability requires coordinated clinical and laboratory practices, supported by meaningful measurement, professional oversight, and continuous quality improvement.
Why Blood Culture Reliability Requires More Than Accurate Laboratory Testing
A blood culture is intended to detect viable microorganisms circulating in the bloodstream. Yet the presence or absence of microbial growth does not independently establish a complete clinical diagnosis.
Bloodstream infection and sepsis are related but distinct conditions. A patient with sepsis may have negative blood cultures, while detecting microorganisms in blood does not automatically establish that the patient has sepsis.
Several factors contribute to this uncertainty. Microorganisms may be present in blood at low concentrations or intermittently. Antimicrobial treatment before specimen collection can reduce the likelihood of recovering viable pathogens. Some organisms are difficult to cultivate using routine blood culture systems, while others require specialized laboratory methods.
At the same time, microorganisms normally present on the skin may enter a culture bottle during collection. When these organisms grow, the result may accurately reflect microbial growth in the specimen even though the organisms were not circulating in the patient's bloodstream.
This distinction between microbial detection and clinical significance is central to blood culture quality.
A laboratory may correctly identify a microorganism introduced through contamination. The analytical process has functioned, but the result may still mislead subsequent clinical decisions if its likely origin and significance are not appropriately assessed.
Conversely, a correctly processed culture may fail to recover a pathogen because the specimen contained insufficient blood or was collected after antimicrobial treatment.
Quality assurance must therefore extend beyond the analytical phase. It should address whether the examination was indicated, whether specimens were collected appropriately, whether laboratory findings are reliable, and whether their limitations are communicated effectively.
The objective is not simply to maximize the number of positive cultures. It is to improve the likelihood that microbiological findings provide accurate and clinically useful information.
Collection Adequacy: Why Blood Volume and Culture Sets Matter
The volume of blood collected is one of the most important factors affecting the sensitivity of blood culture testing.
In adults, microorganisms causing bloodstream infection may be present at relatively low concentrations. An insufficient sample volume reduces the probability that a culture bottle will contain viable organisms, even when infection is present.
CLSI M47, Principles and Procedures for Blood Cultures, second edition, published in April 2022, provides comprehensive recommendations for blood culture collection, transport, processing, interpretation, and reporting.
The guideline also addresses particular circumstances involving pediatric patients, catheter-related infections, infective endocarditis, patients receiving antimicrobial therapy, and microorganisms requiring specialized consideration.
The CDC's adult blood culture quality resources, updated in March 2026, describe a standard collection approach in which an adult blood culture set generally contains 20–30 mL of blood.
Within this framework, collecting at least two sets provides a greater total blood volume for detecting bloodstream infection and additional information for assessing possible contamination.
The CDC describes a standard adult collection practice involving two to four culture sets during the evaluation of a suspected bloodstream infection. Collecting two sets generally provides a total blood volume of approximately 40–60 mL.
These figures provide useful technical references, but they should not be interpreted as universal collection requirements for every patient.
Collection volumes and bottle configurations must reflect the laboratory system, manufacturer instructions, clinical circumstances, and applicable professional procedures.
Pediatric and neonatal blood culture collection requires particular care. Appropriate volumes depend on age, body weight, circulating blood volume, and the child's clinical condition. Adult collection targets should not be applied indiscriminately to these populations.
The distinction between a blood culture bottle and a culture set is also important. A set commonly includes an aerobic and an anaerobic bottle, although the configuration may differ according to the laboratory system and clinical indication. Counting bottles without understanding how they are grouped into sets can lead to inaccurate conclusions about collection adequacy.
The number of venipuncture sites is another consideration.
In routine adult practice, collecting sets through separate peripheral venipunctures is a widely established approach. It can provide useful information when evaluating possible contamination. However, the number of collection sites, culture sets, and bottles are distinct aspects of the collection strategy.
A single venipuncture does not necessarily mean that only one culture set was collected.
The 2026 Surviving Sepsis Campaign guidelines discuss evidence concerning single-site and multiple-site collection strategies. They also recognize that the number of culture sets may need to be individualized, particularly in resource-limited settings.
The guidelines acknowledge circumstances in which collecting a single culture set may be justified when resources are limited.
This should not be interpreted as establishing that one set is universally equivalent to multiple sets. Fewer sets may provide less total blood volume and reduce the information available for distinguishing contamination from genuine bloodstream infection.
The implications depend on the clinical indication, collection method, total blood volume, and available resources.
For healthcare organizations in Viet Nam, the priority is to establish a collection strategy appropriate to the patient population, clinical indication, laboratory system, and service capabilities.
Where deviations from routine procedures are clinically justified, their implications for diagnostic reliability should be recognized.
Preventing Contamination Begins at Specimen Collection
Blood culture contamination commonly occurs when microorganisms enter a specimen during collection or subsequent handling.
The patient's skin is an important potential source, although contamination may also involve collection equipment, catheter components, or other elements of the collection process.
Preventing contamination therefore requires attention to the entire workflow rather than relying solely on the laboratory instrument.
The CDC emphasizes appropriate patient identification, skin antisepsis, disinfection of blood culture bottle septa, suitable collection technique, and prompt transport to the laboratory.
Collection procedures should also establish how specimens are labeled and how relevant information is documented. The collection time, anatomical site, method, and identity of the person obtaining the specimen may be important for traceability and subsequent quality review.
Peripheral venipuncture is generally preferred for routine diagnostic blood culture collection when appropriate. Specimens obtained through indwelling vascular catheters may have additional contamination risks, although catheter sampling can be clinically necessary for selected diagnostic questions.
Suspected catheter-related bloodstream infection may require specific collection and interpretation procedures. The appropriate approach should be determined by qualified professionals according to the clinical circumstances and relevant guidance.
Personnel collecting cultures need practical competence in the approved procedures. Maintaining collection quality, however, also depends on suitable equipment, clear instructions, adequate supplies, and working conditions that allow aseptic techniques to be performed consistently.
Repeated contamination problems should not automatically be attributed to individual negligence.
A department may have well-trained personnel but experience inconsistent collection quality because of excessive workload, inadequate supplies, poorly designed collection areas, or unclear responsibilities.
Quality improvement should investigate these conditions rather than assume that additional training alone will resolve every problem.
Timing of Collection and the Importance of Timely Treatment
Antimicrobial treatment can reduce the likelihood of recovering viable microorganisms from blood.
When bloodstream infection or sepsis is suspected, obtaining cultures before antimicrobial administration can improve the opportunity to identify the causative pathogen.
The 2026 Surviving Sepsis Campaign guidelines recommend collecting blood cultures as soon as possible in adults with possible, probable, or definite sepsis or septic shock, ideally before antimicrobial therapy.
This is a strong recommendation based on evidence rated as low certainty.
Importantly, the guidelines do not support delaying urgently needed antimicrobial treatment to complete blood culture collection.
This balance is essential for patient safety.
A healthcare organization should not introduce a performance target that encourages clinicians to postpone treatment in a time-critical situation merely to achieve a preferred specimen collection sequence.
Instead, clinical workflows should support timely cultures and timely treatment together.
This may require coordination among emergency clinicians, nursing personnel, specimen collection teams, and laboratory services so that appropriate sampling occurs promptly without creating unnecessary barriers to care.
When blood cultures are collected after antimicrobial exposure, that information may be relevant to interpretation, particularly if the cultures remain negative.
The circumstances of collection may also help explain differences between results obtained at different stages of the patient's illness.
The quality concern is not whether every culture was obtained under ideal conditions. It is whether relevant limitations are recognized and considered when the findings are used in clinical decision-making.
Blood Culture Contamination as a Diagnostic Safety Problem
A contaminated blood culture may initiate a chain of clinical decisions based on a finding that does not represent genuine bloodstream infection.
The consequences can extend beyond unnecessary antimicrobial treatment. Patients may undergo additional blood sampling, imaging, specialist consultation, or investigations to locate a suspected source of infection. In some circumstances, contaminated cultures may contribute to unnecessary vascular device removal or prolonged hospitalization.
These consequences have implications for patient safety, antimicrobial stewardship, and healthcare resource use.
A study by Acker and Poonawala, published in Infection Control & Hospital Epidemiology in 2026, examined 525 cases of blood culture contamination.
The investigators found that 71.2% of these contamination cases involved cultures ordered for clinical indications considered to have a low risk of bacteremia.
The study also identified unnecessary testing and antimicrobial use associated with contaminated cultures.
This finding highlights the relationship between appropriate test ordering and contamination-related harm.
However, the reported percentage must be interpreted carefully. It does not mean that 71.2% of all blood cultures are unnecessary, nor does it establish contamination rates in hospitals outside the study setting.
Rather, the investigation illustrates how a culture ordered in a low-probability clinical situation can produce a misleading positive finding and lead to further interventions.
Diagnostic stewardship therefore matters alongside collection technique.
Reducing inappropriate testing may help prevent some contamination-related consequences, provided clinically indicated cultures are not omitted.
The objective is to improve the appropriateness and reliability of testing, not simply reduce the number of specimens collected.
Distinguishing Contamination From Genuine Bloodstream Infection
One of the most challenging aspects of blood culture interpretation is determining whether an isolated organism represents genuine infection.
The answer cannot always be established from the microorganism's identity alone.
Coagulase-negative staphylococci, for example, are commonly associated with skin contamination. However, they can also cause clinically significant bloodstream infections, particularly in patients with central venous catheters, implanted medical devices, or other relevant risk factors.
Other organisms, including Staphylococcus aureus, many Enterobacterales, and Candida species, generally warrant serious clinical consideration when recovered from blood, even when only one culture set is positive.
Interpretation should consider the recovered organism, the number and pattern of positive sets, the patient's condition, relevant risk factors, and the circumstances of specimen collection.
The time required for a culture to become positive may provide additional information. However, time to positivity is not a definitive method for distinguishing contamination from genuine infection. It can be influenced by organism characteristics, blood volume, antimicrobial exposure, specimen transport, and laboratory system performance.
Recovery of the same organism from multiple independently collected sets may increase confidence that the finding represents genuine bloodstream infection.
Conversely, recovery of a common skin commensal from only one of several sets may raise the possibility of contamination.
Neither observation should be interpreted without considering the clinical context.
This becomes particularly important when only one set was collected. Without additional cultures, the laboratory and treating team may have less evidence available to distinguish contamination from genuine infection.
Blood culture interpretation should be understood as a collaborative process.
The microbiology laboratory contributes organism identification, culture characteristics, relevant technical information, and appropriate interpretive comments.
The treating team contributes information about the patient's condition, suspected source of infection, risk factors, and clinical course.
Where appropriate, consultation with microbiology, infectious diseases, or antimicrobial stewardship professionals can help address uncertainty.
Laboratory comments should communicate relevant possibilities without presenting an uncertain interpretation as a confirmed clinical conclusion.
The objective is to support informed professional judgment rather than replace it with rigid rules based on a single microbiological finding.
Understanding the Limitations of Negative Blood Cultures
A negative blood culture is sometimes interpreted as evidence that bloodstream infection is absent.
Such an interpretation may be unjustified.
Blood cultures can remain negative in patients with clinically significant infection. Potential explanations include antimicrobial exposure before collection, inadequate blood volume, intermittent or low-level bloodstream infection, and microorganisms that are not readily recovered by routine methods.
The probability of detecting an organism also depends on the underlying clinical condition and the suitability of the examination.
A negative result should therefore be understood as an observation made under particular testing conditions, rather than an absolute statement about the absence of infection.
This distinction has practical consequences.
Where specimens were collected under conditions likely to reduce sensitivity, the negative result may require more cautious interpretation.
The laboratory can support clinical assessment by making relevant information about specimen adequacy and technical limitations available to the professionals using the result.
However, a negative culture does not automatically justify repeat sampling.
Additional blood cultures or other investigations should be considered according to the patient's clinical condition, suspected diagnosis, and applicable professional guidance.
Indiscriminate repeat testing may introduce further contamination, increase workload, and expose patients to unnecessary procedures.
Conversely, repeat cultures may be clinically important in selected bloodstream infections, particularly when documenting clearance of certain pathogens is required.
Reliable diagnosis involves recognizing both the information a negative culture provides and the uncertainty that remains.
Measuring Blood Culture Contamination Reliably
Contamination surveillance can reveal recurring weaknesses that may not be apparent from individual patient records.
A hospital may identify higher rates of probable contamination in particular departments, collection locations, or operational periods. These patterns can help determine where further investigation is needed.
Meaningful surveillance, however, depends on clearly defined measures.
The CDC's Prevent Adult Blood Culture Contamination quality resource, updated in March 2026, provides a framework built around two complementary indicators: the Blood Culture Contamination Rate and the Single-Set Blood Culture Rate.
These indicators address related but different aspects of collection quality.
The primary contamination measure uses a standardized microbiological definition of probable contamination.
Under the CDC methodology, eligible blood culture sets are obtained from adults aged 18 years or older for whom at least two sets were collected within a 24-hour period.
A probable contamination event may be identified when a designated common skin commensal organism is recovered from only one of the sets, without recovery of the same organism from the other sets collected during that period.
The rate is calculated by dividing the number of eligible blood culture sets meeting the probable contamination definition by the total number of eligible sets collected during the measurement period, multiplied by 100.
The CDC recommends calculating and reporting the contamination rate at least monthly.
An important distinction must be maintained. Probable contamination under a surveillance definition is not necessarily a definitive clinical diagnosis of contamination in an individual patient.
A common skin commensal can cause genuine infection under particular circumstances. The treating team must therefore interpret the result using the available clinical evidence.
The accompanying Single-Set Blood Culture Rate addresses situations in which only one culture set was collected during the defined 24-hour period.
These collections are not eligible for inclusion in the primary contamination measure because the required multiple-set comparison is unavailable. They should nevertheless be monitored rather than ignored.
In the CDC methodology, the single-set rate is calculated separately by dividing the number of qualifying single-set collections by the total number of blood culture sets collected during the measurement period, multiplied by 100.
The denominator includes both sets collected as part of multiple-set episodes and qualifying single sets within the defined surveillance population.
This distinction helps prevent misleading conclusions.
A hospital could appear to have a low contamination rate while collecting only one set from a substantial proportion of adult patients. Without measuring single-set collection, the organization might overlook an important limitation in diagnostic practice.
The two indicators should therefore be interpreted together.
However, the CDC methodology was developed for adult blood culture quality assessment in the United States. Its standard surveillance population includes adults in hospital departments, with institutions able to choose whether to include outpatients.
It should not be applied unchanged to pediatric or neonatal populations, nor should it automatically be treated as a legal requirement for healthcare facilities in Viet Nam.
Where organizations adopt alternative collection strategies because of clinical circumstances or resource limitations, they should establish how those practices will be recorded and analyzed.
Comparisons between hospitals should also account for differences in surveillance definitions, collection practices, eligible patient populations, and denominators.
A contamination rate has limited comparative value when different organizations are not measuring the same process.
Measuring Reliability Beyond the Contamination Rate
Although contamination surveillance is important, it does not capture every dimension of blood culture reliability.
Collection volume deserves separate attention. A laboratory may maintain a low contamination rate while consistently receiving specimens with insufficient blood volumes. Under those circumstances, negative cultures may be less informative than the contamination indicator suggests.
Quality monitoring may therefore include the proportion of culture bottles or sets meeting the validated volume targets for the relevant system and patient population.
The organization may also assess whether locally established requirements for culture sets are being followed, while recognizing documented clinical exceptions.
The relationship between culture collection and antimicrobial administration can be another useful process measure in selected patient groups. Its definition, however, should not encourage inappropriate delays in urgent treatment.
Other relevant indicators may address completeness of collection documentation, specimen transport, equipment performance, or the timeliness of professional review of significant positive findings.
These measures concern different aspects of reliability and should not be combined into a single performance score without a clear and justified methodology.
For example, a high culture positivity rate does not necessarily demonstrate superior collection quality. It may reflect a patient population with a greater prevalence of bloodstream infection.
Similarly, fewer blood cultures do not necessarily indicate better diagnostic stewardship if clinically justified examinations are being omitted.
A low contamination rate is desirable, but it does not establish that specimens were collected in adequate volumes or that recovered microorganisms were interpreted appropriately.
Each indicator should therefore have a clearly defined purpose, numerator, denominator, eligible population, data source, and review frequency.
Where exceptions are permitted, the methodology should explain how they are handled.
Periodic review of selected cases can complement numerical surveillance by examining the clinical circumstances surrounding problematic results.
The purpose of measurement is to identify weaknesses that can be improved, rather than simply produce favorable statistics.
What Recent Evidence Adds to Blood Culture Quality Improvement
Several publications in 2026 have strengthened the connection between blood culture quality, diagnostic stewardship, and patient safety.
A systematic review by López-Rodríguez and colleagues, published in the Journal of Hospital Infection in September 2026, synthesized clinical practice guidelines and evidence-based recommendations relevant to blood culture diagnostic stewardship.
The review addressed appropriate test ordering, specimen collection, blood volume, contamination prevention, and improvement across the testing pathway.
Its findings support the importance of coordinated clinical and laboratory responsibilities rather than treating blood culture quality as an exclusively analytical concern.
The 2026 Surviving Sepsis Campaign guidelines provide an important update concerning timely blood culture collection and the need to balance diagnostic sampling with urgent treatment.
They also recognize that collection strategies may require adaptation in resource-limited circumstances. Such flexibility, however, should not be interpreted as eliminating the importance of specimen adequacy, appropriate technique, or recognition of diagnostic uncertainty.
A multisociety position paper led by Rhee and colleagues, published in Clinical Infectious Diseases in August 2026, further examined hospital strategies to improve sepsis outcomes.
The paper recommends optimizing blood culture ordering practices, including appropriate indications for initial and follow-up cultures.
It also recommends implementing multiplex nucleic acid amplification tests on positive blood cultures, paired with active antimicrobial stewardship support, to promote timely interpretation, treatment optimization, and appropriate follow-up.
These recommendations address different stages of the diagnostic process.
Appropriate ordering reduces unnecessary testing and the potential consequences of contamination. Reliable collection improves the quality of the specimen. Laboratory processing provides microbiological information, while clinical interpretation and antimicrobial stewardship help determine how the findings should influence patient management.
The multisociety position paper was developed primarily for healthcare settings in the United States, and its recommendations should be considered in relation to local resources and service capabilities.
These publications do not establish that any single quality intervention will produce identical benefits in every hospital.
They reinforce a practical conclusion: improving bloodstream infection diagnosis requires an integrated approach involving test appropriateness, collection adequacy, analytical reliability, and professional interpretation.
Professional Accountability Across the Blood Culture Process
Blood culture quality depends on the work of several professional groups.
Laboratory leadership is responsible for maintaining appropriate quality management arrangements, ensuring that examination methods are controlled, and establishing procedures for investigating potentially misleading findings.
Personnel collecting blood cultures need the training, competence, and authorization appropriate to their duties.
Clinicians ordering and interpreting cultures must consider the indication, the patient's condition, and the clinical significance of the results.
Infection prevention teams can contribute to surveillance of contamination patterns and review of specimen collection practices, while antimicrobial stewardship personnel can help assess the implications of microbiological findings for responsible antimicrobial use.
These responsibilities should be coordinated rather than managed as unrelated activities.
For example, when a laboratory identifies repeated probable contamination in one clinical department, simply reporting the rate to its leadership may be insufficient.
An effective investigation may examine collection locations, procedural compliance, staff competence, availability of supplies, and operational pressures.
The findings may reveal that the main weakness is not inadequate knowledge but a workflow that makes consistent collection difficult. Corrective actions should respond to the identified causes.
The same principle applies when blood volumes are consistently below the laboratory's intended targets. Repeated reminders may achieve little if collection equipment, instructions, or staffing arrangements make the expected process difficult to follow.
Healthcare organizations should also ensure that important microbiological findings are appropriately reviewed and communicated within established clinical processes.
Although detailed management of critical diagnostic result communication is outside the principal scope of this article, blood culture interpretation must connect with those arrangements.
A significant microbiological finding should not be assumed to have received appropriate clinical consideration merely because it has been transmitted electronically.
Applying International Guidance Within Viet Nam's Healthcare System
Blood culture services in Viet Nam operate across healthcare facilities with different patient populations, laboratory capacities, staffing arrangements, and access to specialist microbiology expertise.
Some hospitals use automated blood culture systems and advanced identification technologies. Other facilities rely on more limited laboratory resources or referral arrangements for specialized investigations.
These differences influence how quality improvement can be implemented.
CLSI M47 provides an appropriate technical reference for blood culture collection, processing, interpretation, and reporting. However, it is an international professional guideline and should not automatically be presented as a statutory requirement applicable to every Vietnamese healthcare facility.
The national standard TCVN ISO 15189:2025, Medical Laboratories: Requirements for Quality and Competence, is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014.
It provides a framework for laboratory quality management, professional competence, risk-based processes, and the reliability of examination results.
However, the existence of TCVN ISO 15189:2025 does not mean that every medical laboratory in Viet Nam is automatically required to obtain ISO 15189 accreditation.
The applicable obligations depend on relevant legislation, authorized activities, contractual commitments, and accreditation arrangements.
Laboratory quality management is also addressed by Circular No. 01/2013/TT-BYT of the Ministry of Health, as subsequently amended.
Circular No. 25/2026/TT-BYT, issued on June 30, 2026 and effective from August 15, 2026, amended Clause 5 of Article 5 of Circular No. 01/2013/TT-BYT.
The revised provision encourages healthcare facilities to participate in external quality assessment programs according to relevant professional specialties, Ministry of Health arrangements for laboratory quality assurance, and recognized international programs.
This amendment should not be interpreted as establishing a universal requirement for automated blood culture systems, a fixed blood culture contamination threshold, or mandatory adoption of CDC surveillance definitions.
Other applicable quality obligations must be considered according to the service and its regulatory circumstances.
The broader legal framework includes the Law on Medical Examination and Treatment No. 15/2023/QH15 and Decree No. 96/2023/ND-CP, as amended where applicable.
These instruments are relevant to healthcare organizations' licensing arrangements, authorized professional activities, technical responsibilities, and conditions of operation.
Blood culture reliability is also relevant to Viet Nam's National Strategy on Antimicrobial Resistance Prevention and Control for 2023–2030, with a vision to 2045, approved under Decision No. 1121/QD-TTg dated September 25, 2023.
Reliable microbiological information can support more appropriate antimicrobial decisions and strengthen antimicrobial stewardship.
However, this policy connection should not be confused with a specific national requirement for every hospital to achieve identical blood culture performance targets.
Healthcare organizations should distinguish applicable Vietnamese legal obligations from international professional guidance and additional quality indicators adopted through institutional policies or voluntary improvement programs.
The objective is to adapt evidence-informed practices responsibly, taking account of the clinical services provided, patient population, workforce, and available resources.
Using Surveillance Findings to Improve Care
Consider a hospital where monthly surveillance reveals a sustained increase in probable blood culture contamination in a particular clinical department.
The initial question should not be which staff member is responsible. It should be whether the observed increase reflects a genuine change in collection quality, differences in patient characteristics, modifications to collection practices, or problems with the surveillance methodology.
Reviewing collection locations, specimen volumes, the number of sets obtained, staff competence, and the distribution of contamination events may help identify contributing factors.
The hospital can then consider focused interventions based on the findings. These may involve practical competence reassessment, improvements in collection arrangements, clearer procedures, or changes in how suspected contamination is reviewed.
Subsequent surveillance can help determine whether the interventions are associated with better performance.
The same approach may be applied to recurring problems involving inadequate blood volume, unexpected negative cultures, or inconsistent interpretation of clinically important positive findings.
An effective quality program should be able to trace a concern from identification through professional review, corrective action, and reassessment.
A contamination rate that remains above the organization's accepted level despite repeated reporting suggests that additional investigation or improvement may be necessary.
Conversely, a falling contamination rate should be interpreted alongside other measures to ensure that the apparent improvement is not simply the result of collecting fewer culture sets or changing surveillance eligibility.
Surveillance becomes meaningful when it supports learning and improvements in practice rather than functioning only as a reporting requirement.
Over time, this approach can strengthen coordination among laboratory professionals, clinical departments, infection prevention teams, and antimicrobial stewardship services.
Strengthening Blood Culture Reliability as Part of Diagnostic Excellence
Blood culture quality is often discussed primarily in terms of contamination prevention, but its implications for diagnostic care are broader.
Adequate specimen collection can improve the likelihood of recovering a bloodstream pathogen. Effective contamination surveillance can reveal recurring problems that produce misleading positive findings. Appropriate clinical interpretation can help prevent unnecessary responses to likely contaminants while ensuring that genuine infections receive serious consideration.
None of these elements is sufficient on its own.
A sophisticated laboratory cannot fully compensate for persistently inadequate blood collection. A low contamination rate does not establish that negative cultures are reliable. Correct identification of a microorganism does not guarantee an appropriate clinical decision without considering the patient and the circumstances of testing.
For healthcare organizations in Viet Nam, improving blood culture reliability means treating the examination as a connected diagnostic process while maintaining clear responsibilities for its individual stages.
The aim is not to collect the greatest number of cultures, achieve the highest positivity rate, or eliminate every uncertain finding. It is to obtain microbiological information that is as reliable and clinically meaningful as possible, recognize its limitations, and support its responsible use in patient care.
A reliable blood culture result is valuable not simply because a microorganism grows or fails to grow. Its value depends on whether the specimen was collected appropriately, the finding is interpreted in its clinical context, and the healthcare organization can identify and improve the processes that influence diagnostic reliability.
Selected References and Regulatory Sources
Clinical and Laboratory Standards Institute. CLSI M47: Principles and Procedures for Blood Cultures. Second edition. Published April 22, 2022.
Centers for Disease Control and Prevention. Prevent Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals. Updated March 31, 2026. Includes the Blood Culture Contamination Rate primary measure and the Single-Set Blood Culture Rate sub-measure.
Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Intensive Care Medicine. 2026;52:863–936. DOI: 10.1007/s00134-026-08361-1.
Rhee C, Masur H, Klompas M, et al. IDSA/ACEP/ASM/PIDS/SCCM/SHEA/SHM/SIDP Multisociety Position Paper: Hospital Strategies to Improve Sepsis Outcomes. Clinical Infectious Diseases. Published August 25, 2026. DOI: 10.1093/cid/ciag438.
López-Rodríguez M, Álvarez-Fernández A, Smithson A, et al. Diagnostic Stewardship for Optimizing Blood Culture Practices: A Systematic Review of Clinical Practice Guidelines and Evidence-Based Recommendations. Journal of Hospital Infection. 2026;175:159–166. DOI: 10.1016/j.jhin.2026.06.024.
Acker WW, Poonawala H. Can Diagnostic Stewardship Reduce the Harms of Blood Culture Contamination? Infection Control & Hospital Epidemiology. 2026;47(3):322–324. DOI: 10.1017/ice.2025.10381.
Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clinical Infectious Diseases. Published March 5, 2024. DOI: 10.1093/cid/ciae104.
International Organization for Standardization. ISO 15189:2022. Medical Laboratories: Requirements for Quality and Competence.
Ministry of Science and Technology of Viet Nam. TCVN ISO 15189:2025. Medical Laboratories: Requirements for Quality and Competence. Identical to ISO 15189:2022 and replacing TCVN ISO 15189:2014.
National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. Effective January 1, 2024, as subsequently amended.
Government of Viet Nam. Decree No. 96/2023/ND-CP, detailing certain provisions of the Law on Medical Examination and Treatment, as amended where applicable.
Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, guiding the implementation of laboratory quality management at medical examination and treatment facilities, as subsequently amended.
Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, amending and supplementing provisions of Circular No. 01/2013/TT-BYT and other Ministry of Health circulars. Issued June 30, 2026. Amendment to Circular No. 01/2013/TT-BYT effective August 15, 2026.
Prime Minister of Viet Nam. Decision No. 1121/QD-TTg, Approving the National Strategy on Antimicrobial Resistance Prevention and Control for 2023–2030, With a Vision to 2045. September 25, 2023.
Professional Scope and Disclaimer
This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety, and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement, and quality improvement.
The content is intended for general professional education and discussion. It does not constitute individualized medical advice, a clinical or laboratory diagnosis, an antimicrobial treatment protocol, a determination of professional or technical error, an accreditation assessment, certification, or legal advice.
The discussion primarily concerns blood culture reliability in healthcare settings. Specialized circumstances involving pediatric and neonatal patients, infective endocarditis, catheter-related bloodstream infections, immunocompromised patients, unusual pathogens, and resource-limited collection practices require appropriate professional assessment and application of relevant guidance.
References to CLSI, CDC, Surviving Sepsis Campaign, international research, and other professional resources do not imply that their recommendations are automatically mandatory under Vietnamese law. Their applicability depends on the clinical indication, patient population, authorized service capabilities, relevant professional standards, and applicable legal and accreditation requirements.
Patient-specific decisions concerning blood culture indications, specimen collection, laboratory examination, interpretation, repeat testing, additional investigations, antimicrobial treatment, and clinical follow-up must be undertaken by appropriately qualified and authorized healthcare professionals in accordance with applicable Vietnamese law, relevant professional standards, validated institutional procedures, and the patient's clinical circumstances.
Diagnostic Excellence Vietnam does not provide clinical diagnosis, laboratory testing, or treatment services through this educational publication.
